Interferons at age 50: past, current and future impact on biomedicine

By E. Borden, G. Sen, G. Uzé, R. Silverman, R. Ransohoff, G. Foster, G. Stark. Nature reviews. Drug discovery, 2007

1,173 citations recorded by the source corpus.

The family of interferon (IFN) proteins has now more than reached the potential envisioned by early discovering virologists: IFNs are not only antivirals with a spectrum of clinical effectiveness against both RNA and DNA viruses, but are also the prototypic biological response modifiers for oncology, and show effectiveness in suppressing manifestations of multiple sclerosis. Studies of IFNs have resulted in fundamental insights into cellular signalling mechanisms, gene transcription and innate and acquired immunity. Further elucidation of the multitude of IFN-induced genes, as well as drug development strategies targeting IFN production via the activation of the Toll-like receptors (TLRs), will almost certainly lead to newer and more efficacious therapeutics. Our goal is to offer a molecular and clinical perspective that will enable IFNs or their TLR agonist inducers to reach their full clinical potential.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/0ff4e72975dadf2a9d9856be170e4cabf8d9cdb0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system (2020, neutral): “This sequence of events supported the therapeutic use of IFNs in some viral diseases such as chronic hepatitis, but also in non-viral conditions including leukemia and lymphoma, melanoma and multiple sclerosis [17, 18] .”
Interferon-stimulated genes and their antiviral effector functions (2011, neutral): “Type I (IFNα/β) and type III (IL28A, IL28B, IL29) IFNs are often considered the antiviral classes, although type II IFN (IFNγ) also has well-described antiviral properties [4].”
Into the Eye of the Cytokine Storm (2012, background): “Such effects have led to the therapeutic use of IFNs (often in combination with other drugs) in the treatment of viral diseases such as hepatitis C and hepatitis B, certain types of leukemia and lymphoma, and multiple sclerosis (17, 51).”
Interferon-inducible antiviral effectors (2008, background): “Accordingly, IFNs are currently used therapeutically, with the most noteworthy example being the treatment of hepatitis C virus (HCV) infection, and they are also used against various other disorders, including numerous malignancies and multiple sclerosis (reviewed in Ref”
RNase L Amplifies Interferon Signaling by Inducing Protein Kinase R-Mediated Antiviral Stress Granules (2020, background): “Phosphorylated STAT1 translocates to the nucleus to induce transcription of genes regulated by IFN-stimulated response elements (ISRE) (3).”
Toll-like receptors in antiviral innate immunity (2013, background): “In addition, IFNsactivate various innate immune cells and immune effector cells, facilitating the development of adaptive immune responses [25].”